Richard Surosky, PhD; Sangamo Therapeutics (formerly)
Former Senior Director of Vector Production and Development, Sangamo Therapeutics
Dr. Richard Surosky has been engaged in gene therapy research for over twenty-five years. He began his career at Avigen, Inc., an early gene therapy company based in Alameda, CA, developing adeno-associated virus (AAV) as a vector for gene therapy. He later moved to Sangamo Therapeutics in Richmond, CA, where he served as Senior Director for the Vector Production and Development Group. He supervised the Vector Production Core team, which manufactured AAV in support of a variety of research programs. He also helped oversee GMP production of AAV at CMOs in support of Phase I/II and Phase III clinical programs. He has co-authored numerous peer-reviewed publications and presented at many scientific conferences.
Dr. Surosky received his Ph.D. from Cornell University in Molecular and Cellular Biology and did his postdoctoral research at the University of Chicago in the field of yeast molecular genetics. Dr. Surosky retired in 2021, although he continues to consult for several gene therapy companies. He lives in Oakland, CA with his wife, Mae, along with two cats. They are long-time volunteers with two local rescue groups, Hopalong and the Milo Foundation, and have fostered over 400 cats and kittens. He is also a member of the HSUS Animal Rescue Team.